Together, we have established diagnostic pipelines that aim to aid the establishment of an accurate diagnosis and a respective treatment decision both at first diagnosis and relapse.
While a majority of brain tumors can nowadays be cured by surgery and radio-chemotherapy (albeit often at the price of severe long-term side-effects), unfortunately still about 20-25% of patients experience a relapse of their disease. In this situation established treatment options are often lacking. To overcome this shortcoming on the long run we have established a nation-wide program that aims at identifying new molecular drug targets for children who experience relapses from brain tumors, but also with other malignancies.
Here you can find an overview of diagnostic programs (english and german version) that we currently have to offer, which should help to identify the program suitable for your specific case and to plan the steps towards study enrollment. This should always be done via the treating physician. For any details, please read carefully through the table included in the overview.
For all of these programs, please directly contact the respective person mentioned on the program sites. Just sending samples to Heidelberg without a pre-notification of the responsible person will delay the process.
We sincerely hope that with these new possibilities we can serve many of our patients and help informing treating physicians of the appropriate treatment for their patients.